A phase III comparative study of nivolumab (anti-PD-1; BMS-936558; ONO-4538) versus docetaxel in patients with previously treated advanced or metastatic squamous cell non-small cell lung cancer (NSCLC).

被引：0
|
作者：
Borghaei, Hossein
Lynch, Thomas James
Rizvi, Naiyer A.
Chow, Laura Quan Man
Reilly, Robert
Crino, Lucio
Buyse, Marc E.
Ezzeddine, Rana
Lestini, Brian Joseph
Brahmer, Julie R.
机构：
[1] Fox Chase Canc Ctr, Philadelphia, PA 19111 USA
[2] Yale Univ, Sch Med, New Haven, CT USA
[3] Mem Sloan Kettering Canc Ctr, New York, NY 10021 USA
[4] Univ Washington, Seattle, WA 98195 USA
[5] St Mary Hosp, Langhorne, PA USA
[6] Azienda Osped Perugia, Perugia, Italy
[7] Int Inst Drug Dev, Louvain, Belgium
[8] Bristol Myers Squibb Co, Wallingford, CT 06492 USA
[9] Bristol Myers Squibb Co, Princeton, NJ USA
[10] Johns Hopkins Univ, Sidney Kimmel Comprehens Canc Ctr, Baltimore, MD USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2013年 / 31卷 / 15期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
TPS8122
引用
收藏
页数：2
相关论文
共 50 条
  • [1] Nivolumab (anti-PD-1, BMS-936558, ONO-4538) in patients with advanced non-small cell lung cancer
    Rajan, Arun
    Gulley, James L.
    TRANSLATIONAL LUNG CANCER RESEARCH, 2014, 3 (06) : 403 - 405
  • [2] Phase II Study of Nivolumab (anti-PD-1, BMS-936558, ONO-4538) in Patients with Advanced, Refractory Squamous Non-Small Cell Lung Cancer
    Ramalingam, S. S.
    Mazieres, J.
    Planchard, D.
    Stinchcombe, T. E.
    Dy, G. K.
    Antonia, S. J.
    Horn, L.
    Lena, H.
    Minenza, E.
    Mennecier, B.
    Otterson, G. A.
    Campos, L. T.
    Gandara, D. R.
    Levy, B. P.
    Nair, S. G.
    Zalcman, G.
    Wolf, J.
    Baudelet, C.
    Lestini, B. J.
    Rizvi, N. A.
    INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2014, 90 (05): : 1266 - 1267
  • [3] EFFICACY OF NIVOLUMAB (ANTI-PD-1; BMS-936558; ONO-4538) IN PATIENTS WITH PREVIOUSLY TREATED ADVANCED NON-SMALL CELL LUNG CANCER (NSCLC): SUBPOPULATION RESPONSE ANALYSIS IN A PHASE 1 TRIAL
    Gettinger, Scott
    Horn, Leora
    Antonia, Scott J.
    Spigel, David R.
    Gandhi, Leena
    Sequist, Lecia V.
    Sankar, Vindira
    Ahlers, Christoph M.
    Wigginton, Jon M.
    Kollia, Georgia
    Gupta, Ashok
    Brahmer, Julie R.
    JOURNAL OF THORACIC ONCOLOGY, 2013, 8 : S909 - S909
  • [4] Nivolumab (Anti-PD-1; BMS-936558, ONO-4538) Maintenance as Monotherapy or in Combination With Bevacizumab (BEV) for Non-Small Cell Lung Cancer (NSCLC) Previously Treated With Chemotherapy
    Rizvi, N. A.
    Antonia, S. J.
    Shepherd, F. A.
    Chow, L. Q.
    Goldman, J.
    Shen, Y.
    Chen, A. C.
    Gettinger, S.
    INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2014, 90 : S32 - S32
  • [5] NIVOLUMAB (ANTI-PD-1; BMS-936558, ONO-4538) IN PATIENTS WITH ADVANCED NON-SMALL CELL LUNG CANCER (NSCLC): SURVIVAL AND CLINICAL ACTIVITY BY SUBGROUP ANALYSIS
    Rizvi, Naiyer A.
    Gettinger, Scott N.
    Horn, Leora
    Gandhi, Leena
    Spigel, David R.
    Powderly, John D.
    Heist, Rebecca S.
    Carvajal, Richard D.
    Jackman, David M.
    Sequist, Lecia V.
    Smith, David C.
    Leming, Philip D.
    Topalian, Suzanne L.
    Hodi, F. Stephen
    Sznol, Mario
    Harbison, Christopher T.
    Kollia, Georgia D.
    Brahmer, Julie R.
    Antonia, Scott J.
    JOURNAL OF THORACIC ONCOLOGY, 2014, 9 (09) : S152 - S152
  • [6] Phase II studies of nivolumab (anti-PD-1, BMS-936558, ONO-4538) in patients with advanced squamous (sq) or nonsquamous (non-sq) non-small cell lung cancer (NSCLC).
    Nishio, Makoto
    Hida, Toyoaki
    Nakagawa, Kazuhiko
    Sakai, Hiroshi
    Nogami, Naoyuki
    Atagi, Shinji
    Takahashi, Toshiaki
    Nokihara, Hiroshi
    Saka, Hideo
    Takenoyama, Mitsuhiro
    Fujita, Shiro
    Tanaka, Hiroshi
    Takeda, Koji
    Satouchi, Miyako
    Isobe, Hiroshi
    Maemondo, Makoto
    Goto, Koichi
    Hirashima, Tomonori
    Minato, Koichi
    Tamura, Tomohide
    JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (15)
  • [7] A phase III comparative study of nivolumab (anti-PD-1; BMS-963558; ONO-4538) versus docetaxel in patients (pts) with previously treated advanced/metastatic nonsquamous non-small-cell lung cancer (NSCLC).
    Gettinger, Scott N.
    Brahmer, Julie R.
    Rizvi, Naiyer A.
    Ready, Neal
    Chow, Laura Quan Man
    Antonia, Scott J.
    Buyse, Marc E.
    Jassem, Jacek
    Finckenstein, Friedrich Graf
    Crino, Lucio
    Lynch, Thomas James
    JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (15)
  • [8] Phase 2 study of nivolumab (Anti-PD-1; ONO-4538/BMS-936558) in patients with advanced melanoma
    Yamazaki, N.
    Tahara, H.
    Uhara, H.
    Moroi, Y.
    Kiyohara, Y.
    EUROPEAN JOURNAL OF CANCER, 2013, 49 : S868 - S868
  • [9] Safety and Efficacy of First-Line Nivolumab (Anti-PD-1; BMS-936558, ONO-4538) and Ipilimumab in Non-Small Cell Lung Cancer (NSCLC)
    Antonia, S. J.
    Gettinger, S.
    Goldman, J.
    Chow, L. Q.
    Juergens, R.
    Borghaei, H.
    Brahmer, J. R.
    Shen, Y.
    Harbison, C.
    Chen, A. C.
    Ready, N. E.
    Rizvi, N. A.
    INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2014, 90 : S32 - S33
  • [10] A phase III comparative study of nivolumab (anti-PD-1; BMS-936558; ONO-4538) versus everolimus in patients (pts) with advanced or metastatic renal cell carcinoma (mRCC) previously treated with antiangiogenic therapy.
    Motzer, Robert John
    Bono, Petri
    Hudes, Gary R.
    Tomita, Yoshihiko
    Ravaud, Alain
    Waxman, Ian
    Gore, Martin Eric
    JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (15)
12345